Galmed Pharmaceuticals (GLMD) details HEP-DART 2025 abstract in SEC filing

Rhea-AI Filing Summary

Galmed Pharmaceuticals Ltd. filed a Form 6-K noting it issued a press release titled “Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting.” The update highlights that a late-breaking abstract involving the company will be presented at the HEP-DART 2025 Meeting.

The report specifies that this Form 6-K and the first two paragraphs of the attached press release are incorporated by reference into Galmed’s existing Registration Statements on Form S-8 and Form F-3, so this information now also forms part of those offerings.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of December 2025

001-36345

(Commission File Number)

GALMED PHARMACEUTICALS LTD.

(Exact name of Registrant as specified in its charter)

c/o Meitar Law Offices Abba Hillel Silver Rd.,

Ramat Gan, 5250608

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On December 8, 2025, Galmed Pharmaceuticals Ltd. (the “Company”) issued a press release entitled “Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

This Form 6-K and the first two paragraphs of the press release attached hereto as Exhibit 99.1 are hereby incorporated by reference into the Company’s Registration Statements on Form S-8 (Registration Nos. 333-206292, 333-227441, 333-284163, and 333-290399) and the Company’s Registration Statements on Form F-3 (Registration Nos. 333-272722 and 333-283241).

EXHIBIT INDEX

Exhibit No.		Description
99.1		Press Release, dated December 8, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Galmed Pharmaceuticals Ltd.
Date: December 8, 2025	By:	/s/ Allen Baharaff
		Allen Baharaff
		President and Chief Executive Officer

FAQ

What did Galmed Pharmaceuticals (GLMD) report in its December 2025 Form 6-K?

Galmed Pharmaceuticals reported that it issued a press release titled “Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting” and furnished that release as an exhibit.

What is the subject of Galmed Pharmaceuticals' recent press release?

The press release announces the acceptance of a late-breaking abstract that will be presented at the HEP-DART 2025 Meeting.

How does this Form 6-K affect Galmed Pharmaceuticals' registration statements?

The Form 6-K states that it and the first two paragraphs of the attached press release are incorporated by reference into Galmed’s Registration Statements on Form S-8 and Form F-3.

Which specific registration statements does Galmed Pharmaceuticals reference in this filing?

The report references Registration Statements on Form S-8 with numbers 333-206292, 333-227441, 333-284163, and 333-290399, and Registration Statements on Form F-3 with numbers 333-272722 and 333-283241.

When was the related press release issued and who signed the report for Galmed Pharmaceuticals?

The press release is dated December 8, 2025, and the report was signed on behalf of Galmed Pharmaceuticals Ltd. by Allen Baharaff, President and Chief Executive Officer.

What exhibit is attached to Galmed Pharmaceuticals' December 2025 Form 6-K?

The filing includes Exhibit 99.1, which is the press release dated December 8, 2025.